Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial
Why the study?
Does the addition of SSRIs to anticoagulants increase bleeding risk in patients with atrial fibrillation?
Population
1,474 patients with atrial fibrillation taking anticoagulants for the prevention of stroke/systemic embolism…
Comparison
Selective serotonin reuptake inhibitors added to… vs No SSRI added to anticoagulant therapy
Design
Cohort, Propensity score matched 1:1
Follow-up
mean 1.6 years
Authors
Discussion
Loading...
Member takes
Implication
No significant bleeding increase seen with SSRIs plus anticoagulation in AF; leaves open need for randomized confirmation.
Structured PICO
Does the addition of SSRIs to anticoagulants increase bleeding risk in patients with atrial fibrillation?
P
Population
1,474 patients with atrial fibrillation taking anticoagulants (rivaroxaban or warfarin) for the prevention of stroke/systemic embolism from the ROCKET AF trial
I
Intervention
Selective serotonin reuptake inhibitors (SSRIs) added to anticoagulant therapy
C
Comparator
No SSRI added to anticoagulant therapy (propensity score matched 1:1)
O
Outcome
Major and nonmajor clinically relevant bleeding eventssafety
The addition of SSRIs to anticoagulants (rivaroxaban or warfarin) in patients with atrial fibrillation does not significantly increase the risk of major or nonmajor clinically relevant bleeding.
Cite This Study
Quinn et al. (2018) studied this question.